November 20, 2025 — Leads & Copy — Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) announced that the Toronto Stock Exchange (TSX) has approved its intention to conduct a normal course issuer bid (NCIB) for its common shares (TSX: MDP).
Medexus may purchase up to 2,983,650 common shares for cancellation, representing approximately 10% of the public float as defined under TSX rules, according to the announcement. As of November 12, 2025, the company had 32,420,060 common shares outstanding and a public float of 29,836,506 common shares.
Brendon Buschman, Medexus’s Chief Financial Officer, stated that the company intends to monitor the market price of its common shares and that purchases under the NCIB could be an appropriate use of available funds if the market price is undervalued. Buschman added that such purchases would benefit the company and its investors by seeking to maintain a liquid, stable, and orderly market for the company’s common shares.
Purchases may start on November 24, 2025, and continue through November 23, 2026, or until Medexus completes the maximum aggregate purchases permitted under the NCIB. The purchases will be conducted through open market transactions via the TSX or alternative Canadian trading systems at the prevailing market price or as otherwise permitted. Medexus will fund the NCIB from its general funds, and any common shares purchased will be cancelled.
During the six months ending October 31, 2025, the average daily trading volume (ADTV) of the common shares on the TSX was 40,066. Under TSX rules, purchases under the NCIB on any trading day will be limited to a maximum of 10,016 common shares, which is 25% of the ADTV, unless made under the TSX’s block purchase exception.
Medexus is a specialty pharmaceutical company with a North American commercial platform and a growing portfolio of treatment solutions for innovative and rare diseases. The company focuses on hematology and hematology-oncology, rheumatology, and allergy.
Ken d’Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com
Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com
Victoria Rutherford | Adelaide Capital
Tel: 480-625-5772 | Email: victoria@adcap.ca
Source: Medexus Pharmaceuticals
